Breast & Inframammary HS
Inframammary HS — recurring painful nodules, abscesses and sinus tracts under or around the breast — is one of the most hormonally sensitive HS presentations. It is not a hygiene problem, not a consequence of breast size alone, and not a localised skin condition. It is a systemic inflammatory disease with specific hormonal and metabolic drivers that express at a site of particular anatomical vulnerability.
Inframammary HS is driven internally — by hormonal imbalance, metabolic inflammation, and immune dysregulation — not by moisture or friction alone, which are amplifiers rather than causes
The hormonal sensitivity of inframammary HS means that flares frequently track the menstrual cycle — particularly the luteal phase when androgen levels are relatively elevated
Body image and intimacy are significantly affected in ways that patients rarely feel able to discuss; this is a real and important part of the clinical picture
Without addressing hormonal and metabolic root causes, even well-managed local treatment produces a predictable pattern of temporary improvement followed by recurrence
Why the Inframammary Region Is Particularly Vulnerable
The area under and around the breast has specific anatomical and physiological characteristics that explain its vulnerability to HS — particularly in the context of hormonal and metabolic imbalance.
High Follicular and Sebaceous Density
The skin of the inframammary region and the lateral breast contains a high density of hair follicles and sebaceous glands — the structures most directly involved in HS pathology. When hormonal signals drive excess sebaceous activity and follicular hyperkeratosis, this density creates the conditions for multiple simultaneous lesion sites.
This follicular architecture is not changeable — it is the reason the inframammary region is anatomically predisposed to HS expression when internal drivers are present. Addressing the drivers, not the anatomy, is what changes the disease pattern.
Androgen Receptor Sensitivity
The breast skin has significant androgen receptor activity — making it directly responsive to hormonal fluctuations. In women with androgen excess (from PCOS, adrenal dysregulation, or metabolic-driven androgen conversion from adipose tissue), the inframammary region receives amplified hormonal signalling that drives follicular blockage and sebaceous overactivity. This is why inframammary HS reliably tracks the hormonal cycle when androgen patterns are abnormal.
Moisture and Friction — Amplifiers, Not Causes
The inframammary fold retains heat and moisture, and the weight of the breast creates friction on the skin beneath it. These are real factors — but they are amplifiers of an existing internal inflammatory process, not its origin. Patients who address only moisture and friction (different bras, drying agents, powder) typically experience modest improvement followed by persistent recurrence, because the internal drivers remain unchanged.
Understanding this distinction is important: it means that the condition is not caused by breast size, personal hygiene failure, or choice of clothing. It is a systemic disease that the local environment amplifies.
Lymphatic Drainage Pattern
The inframammary region drains through axillary and internal mammary lymphatic chains. When lymphatic function is compromised — as it often is when metabolic factors are present — clearance of inflammatory mediators from this region is impaired, sustaining local inflammatory activity between lesion episodes. The frequent coexistence of inframammary and axillary HS reflects their shared lymphatic territory and shared hormonal and systemic drivers.
The Menstrual Cycle and Inframammary HS Flares
Many women with inframammary HS notice that flares reliably occur at specific points in their menstrual cycle. This is not coincidence — it is a direct physiological relationship between hormonal patterns and disease activity.
Oestrogen and progesterone low. Some patients experience flare resolution as hormonal fluctuation settles.
Rising oestrogen. Generally lower flare activity in patients with oestrogen-dominant patterns. Relative calm phase.
LH surge and androgen peak. Some patients notice lesion activation at or just after ovulation.
Progesterone rises, androgens relatively elevated. This is the primary flare window for most women with inframammary HS — lesions appear 7–10 days before menstruation.
Why the Luteal Phase Triggers Inframammary Flares
During the luteal phase, progesterone rises and oestrogen falls relative to its follicular peak. In women with androgen excess — whether from PCOS, adrenal dysregulation, or adipose tissue androgen conversion — the relative androgen dominance during this phase amplifies follicular sebaceous activity in the inframammary region, driving the follicular blockage that precedes lesion formation.
This cyclical pattern is diagnostically important: if inframammary flares reliably occur in the 10 days before menstruation, hormonal dysregulation is almost certainly a primary driver. The treatment implication is clear — hormonal correction is a central treatment priority, not an optional add-on.
It is worth noting that not all inframammary HS follows a clear cyclical pattern. In women with significant metabolic inflammation or immune dysregulation, disease activity may be more continuous — the hormonal trigger is present but layered on top of a chronically elevated baseline.
In Ayurvedic clinical reasoning, cyclical hormonal HS is understood through the framework of Artava Dushti — disruption of the menstrual tissue system — combined with Pitta and Rakta aggravation. Treatment approaches that address hormonal regulation from this framework work on the endocrine system as a whole, not just individual hormone levels.
What Sustains Inframammary HS from Within
The inframammary region is the site of expression. The drivers that sustain the disease operate systemically — which is why no amount of local management can produce durable improvement without addressing what is happening internally.
Primary Driver
Androgen Excess and Hormonal Imbalance
Elevated androgens — whether from PCOS, adrenal dysregulation, or insulin-driven conversion from adipose tissue — directly stimulate sebaceous gland activity and promote follicular hyperkeratosis in the inframammary region. This is the most directly actionable driver in most inframammary HS cases. Hormonal recalibration — restoring appropriate androgen-oestrogen balance and addressing the source of androgen excess — is the central treatment target.
Primary Driver
Insulin Resistance and Metabolic Inflammation
Insulin resistance amplifies androgen production through the insulin-androgen axis — elevating circulating androgens independently of ovarian or adrenal function. It also generates systemic low-grade inflammation that sustains immune activation in the inframammary region. In patients with significant metabolic disruption, metabolic correction is as important a treatment target as direct hormonal intervention — because metabolic factors are driving the hormonal imbalance.
Significant Driver
Immune Dysregulation
The dysregulated immune response — excessive inflammatory signalling in response to follicular triggers — determines the severity of inframammary HS episodes. When hormonal triggers are present and immune dysregulation is active, even small follicular disruptions produce significant inflammatory cascades. Systemic immune recalibration reduces the disproportionality of this response, so that hormonal fluctuations no longer reliably produce full HS episodes.
Significant Driver
Gut Dysbiosis
Disrupted gut microbiome contributes to immune dysregulation and can affect oestrogen metabolism — the gut microbiome is directly involved in the enterohepatic circulation of oestrogens. Gut dysbiosis that impairs oestrogen clearance can worsen oestrogen-androgen imbalance and amplify the hormonal driver of inframammary HS. Gut restoration is therefore relevant both as an immune correction measure and as a supporting hormonal intervention.
Amplifying Factor
Adipose Tissue and Weight
Adipose tissue — particularly in the breast region — is metabolically active and converts adrenal androgens to oestrogens and other hormones through aromatase activity. In women with excess adipose tissue, this amplifies the hormonal imbalance driving inframammary HS. Additionally, increased inframammary fold depth increases friction and moisture retention. Metabolic weight correction — not simply caloric restriction — is part of comprehensive treatment in relevant cases.
Amplifying Factor
Stress and Cortisol
Chronic stress elevates cortisol, which disrupts the hypothalamic-pituitary-adrenal axis — amplifying adrenal androgen production and worsening the hormonal driver of inframammary HS. Many patients notice that high-stress periods reliably worsen their inframammary disease activity, independently of cycle phase. Stress regulation is addressed as a therapeutic component, not a lifestyle suggestion.
Body Image, Intimacy, and the Burden of Inframammary HS
What Patients Rarely Feel Able to Say
Inframammary HS affects one of the most personally significant areas of the body for many women. Active lesions, scarring, discharge, and odour in the breast region affect how women relate to their own bodies — and how they experience intimacy. The combination of physical pain and emotional impact is significant and often carried silently, because the location makes it difficult to discuss even with trusted people.
Many women with inframammary HS develop patterns of avoidance — avoiding physical closeness, avoiding certain clothing, avoiding activities that cause heat and perspiration — that progressively narrow their lives. These patterns are understandable responses to a condition that causes real physical discomfort and emotional vulnerability. They are also, over time, isolating.
Acknowledging this dimension of inframammary HS is not a distraction from clinical management — it is part of understanding the full cost of the condition and why effective treatment matters beyond simple symptom reduction. Patients who feel their experience is understood are more engaged in treatment and more likely to make the sustained changes that root-cause correction requires.
The goal of treatment is not just reduced lesion frequency — it is restored physical and emotional freedom. That goal shapes how treatment is approached and communicated.
How Inframammary HS Develops Step by Step
Hormonal and Metabolic Priming
Androgen excess, insulin resistance, and gut-derived inflammatory input create a systemic state that primes the inframammary region for HS activity. The androgen receptor density of the breast skin means it is particularly responsive to the hormonal environment. During the luteal phase, when androgens are relatively elevated, this priming converts into active follicular disruption. In patients with continuous metabolic inflammation, the priming state never fully resolves between cycles.
Follicular Hyperkeratosis and Blockage
Androgen stimulation drives excess keratin production in the follicular lining and excess sebum production in the sebaceous gland. The combination blocks the follicular canal. In the inframammary region, moisture and friction from the breast fold prevent the natural shedding that might otherwise allow resolution. The blocked follicle accumulates material under increasing pressure.
Follicular Rupture and Immune Cascade
Follicular wall rupture releases contents into the surrounding dermis, triggering the dysregulated immune response. The immune system — already in a heightened state from systemic hormonal and inflammatory priming — responds disproportionately, producing the painful inflammatory nodule. In the inframammary region, the proximity of multiple follicular units means one rupture often triggers adjacent lesion formation rapidly.
Abscess Formation and Partial Healing
The inflammatory response produces abscess formation — painful, fluctuant collections that may drain spontaneously or require intervention. In the inframammary location, drainage is mechanically complicated by the overlying breast tissue. The episode partially resolves, often leaving scarring and fibrotic change, before the hormonal cycle renews the priming conditions for the next episode.
Sinus Tract Formation with Progression
Without root-cause correction, repeated cycles produce sinus tracts connecting lesion sites across the inframammary fold and adjacent breast skin. These tracts are structurally permanent and serve as reservoirs for ongoing inflammation — and their presence under the breast creates hygiene and management challenges that further compound the burden of the condition.
"If inframammary HS flares predictably before each period, the hormonal driver is not being addressed — it is being endured. Cyclical recurrence is not an inevitable feature of the condition; it is a signal that the internal hormonal pattern has not been corrected."
Why Inframammary HS Keeps Coming Back
Each recurrence signal below is a specific unresolved driver. When these are active, recurrence is not a failure of local treatment — it is a predictable consequence of leaving systemic causes unaddressed.
Hormonal Cycle Not Corrected Androgen excess continues to drive follicular hyperkeratosis with each luteal phase. Flares follow the hormonal cycle because the hormonal driver is still active. Local treatment cannot interrupt a systemic hormonal pattern.
Insulin Resistance Persists Ongoing insulin resistance continues to amplify androgen production and sustain systemic inflammation — maintaining the hormonal environment that drives inframammary HS activity regardless of menstrual phase.
Immune Dysregulation Unreached The disproportionate immune response pattern continues to execute with each hormonal trigger. Without recalibration, each luteal phase androgen surge reliably produces the full inflammatory cascade.
Gut Dysbiosis — Oestrogen Metabolism Impaired Disrupted gut microbiome impairs oestrogen clearance, worsening the oestrogen-androgen imbalance that drives inframammary HS. Gut correction is therefore a hormonal treatment target, not only an immune one.
Established Sinus Tracts Once sinus tracts have formed in the inframammary region, they serve as persistent inflammatory reservoirs and focal points for new disease activity — independent of whether a hormonal trigger is present.
Local Conditions Unaddressable Moisture, friction, and heat under the breast cannot be fully eliminated. These amplifiers ensure that when internal drivers are active, inframammary lesion formation is reliably triggered — making systemic correction the only effective long-term approach.
How Inframammary HS Progresses Without Root-Cause Treatment
Understanding the stages of inframammary HS progression clarifies both what is at stake in delayed treatment and why the approach that addresses root causes produces qualitatively different outcomes.
Cyclical Nodules, Clear Hormonal Pattern
Painful nodules appearing pre-menstrually, resolving partially
Clear cyclical pattern — lesions tracking the luteal phase
No established sinus tracts; structural change minimal
Often dismissed as "hormonal skin issues" — correct diagnosis delayed
Ideal stage for hormonal root-cause intervention
Multiple Sites, Incomplete Resolution, Early Tracts
Multiple simultaneous lesions across inframammary fold
Partial resolution between cycles — no longer fully clear
Early sinus tract connections forming
Scarring altering skin texture; discharge between episodes
Body image and intimacy significantly affected
Sinus Tract Network, Continuous Disease Activity
Interconnected sinus tract network across inframammary region
Continuous or near-continuous discharge
Disease extending onto breast skin or lateral chest
Significant fibrosis and permanent structural change
Root-cause treatment still meaningful — longer timeline
What a Root-Cause Approach to Inframammary HS Addresses
Treatment of inframammary HS follows the EPOH Protocol — a structured, phase-based approach adapted to each patient's specific driver profile. The hormonal dimension is prominent in most inframammary cases, but the treatment framework addresses all active drivers comprehensively.
The primary treatment target in most inframammary HS cases. Personalised formulations designed to reduce androgen excess, restore appropriate oestrogen-progesterone-androgen balance, and address the specific hormonal imbalance pattern identified in each patient. For PCOS-linked cases, this includes ovarian function support. For adrenal-driven cases, adrenal regulation is the focus. For metabolically driven androgen excess, metabolic correction provides the primary hormonal benefit. This phase does not suppress hormones — it recalibrates the system so that the cyclical androgen surges that drive inframammary HS no longer produce follicular disruption.
Insulin resistance is addressed through dietary correction, metabolic support formulations, and lifestyle guidance. Reducing insulin-driven androgen amplification is a direct hormonal treatment — the metabolic and hormonal phases are deeply interconnected in inframammary HS. Dietary adjustments are individualised based on each patient's metabolic profile, not a generic low-glycaemic protocol. As metabolic correction progresses, the androgen excess it was sustaining reduces in parallel.
Gut microbiome restoration corrects both the immune driver and — importantly in inframammary HS — the oestrogen metabolism disruption caused by dysbiosis. The gut microbiome's role in enterohepatic oestrogen circulation means that gut health directly influences hormonal balance. Restoring gut health therefore provides hormonal benefit alongside immune correction, making it a dual-target phase in inframammary HS management.
Formulations targeting immune dysregulation — reducing the disproportionate inflammatory response to follicular triggers. As the immune response is recalibrated in the context of improving hormonal and metabolic balance, the threshold for lesion formation rises significantly. Patients typically notice at this phase that hormonal fluctuations that previously reliably produced flares are no longer doing so.
Tissue repair formulations support healing of the inframammary region — reducing fibrotic changes, supporting follicular structural normalisation, and improving the skin quality of the affected area. Long-term stabilisation through Rasayana formulations maintains the corrected hormonal, metabolic, and immune state — sustaining remission and preventing reactivation across future hormonal cycles.
Herbal Formulations for Inframammary HS Reversal
Formulations for inframammary HS are built around each patient's specific hormonal, metabolic, and immune profile. The targets below represent the functional areas addressed — not a standard protocol.
Formulation Target
Hormonal Regulation Formula
Personalised formulations targeting androgen excess, oestrogen-progesterone balance, and adrenal-ovarian-metabolic endocrine regulation. For PCOS-linked inframammary HS, ovarian function support is central. For adrenal-driven cases, HPA axis regulation is the focus. Formulation is adapted to the patient's specific hormonal pattern — not a generic "hormonal balance" supplement.
Formulation Target
Insulin-Androgen Axis Correction
Formulations supporting insulin sensitivity and metabolic correction — directly reducing the insulin-driven androgen amplification that sustains inframammary HS in metabolically affected patients. Works in combination with dietary correction to address the metabolic root of hormonal imbalance.
Formulation Target
Blood Purification & Inflammatory Load Reduction
Formulations reducing the systemic inflammatory burden — lowering the baseline that determines how severely the immune system responds to hormonal triggers. As inflammatory load decreases, the inframammary region becomes progressively less reactive to the androgen fluctuations of the luteal phase.
Formulation Target
Gut Restoration & Oestrogen Metabolism Support
Gut restoration formulations that address both immune dysregulation and oestrogen metabolism — a dual-target relevant specifically to inframammary HS. Restoring gut microbiome balance improves the enterohepatic oestrogen circulation that dysbiosis disrupts, providing direct hormonal benefit alongside immune correction.
Formulation Target
Skin Healing & Scar Reduction Blend
Formulations supporting dermal regeneration, fibrosis reduction, and follicular structural normalisation in the inframammary region. Most relevant once active inflammation has been brought under control through hormonal and metabolic correction. Supports the physical recovery of the affected skin alongside the internal corrections.
Formulation Target
Stabilisation Rasayana
Long-term rejuvenating formulations maintaining the corrected hormonal, metabolic, and immune state across future cycles. These define the transition from cyclical management to sustained remission — the internal environment is maintained so that luteal phase hormonal fluctuations no longer trigger inframammary HS activity.
Other HS Presentations
Inframammary HS frequently coexists with axillary and groin HS — sharing hormonal and systemic drivers. Understanding the full multifocal picture informs comprehensive treatment planning.
If Inframammary HS Returns Every Cycle, the Hormonal Pattern Has Not Been Addressed
A personalised evaluation identifies the specific hormonal, metabolic, and immune factors sustaining your inframammary HS — and maps a structured treatment approach that targets what is actually driving it. Cyclical recurrence is a pattern that can be interrupted, not a permanent feature of the condition.